MX2010005824A - Derivados de aminotiazol. - Google Patents

Derivados de aminotiazol.

Info

Publication number
MX2010005824A
MX2010005824A MX2010005824A MX2010005824A MX2010005824A MX 2010005824 A MX2010005824 A MX 2010005824A MX 2010005824 A MX2010005824 A MX 2010005824A MX 2010005824 A MX2010005824 A MX 2010005824A MX 2010005824 A MX2010005824 A MX 2010005824A
Authority
MX
Mexico
Prior art keywords
aminothiazole derivatives
aminothiazole
derivatives
esters
compounds
Prior art date
Application number
MX2010005824A
Other languages
English (en)
Inventor
Paul Hebeisen
Hans Peter Wessel
Eric A Kitas
Rudolf E Minder
Peter Mohr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010005824A publication Critical patent/MX2010005824A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Se describen compuestos de la fórmula (I) (ver fórmula (I)) así como las sales y ésteres farmacéuticamente aceptables de los mismos, en la que de R1 a R3 tienen los significados definidos en la reivindicación 1 y que pueden utilizarse en forma de composiciones farmacéuticas.
MX2010005824A 2007-11-30 2008-11-20 Derivados de aminotiazol. MX2010005824A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122019 2007-11-30
PCT/EP2008/065910 WO2009068467A1 (en) 2007-11-30 2008-11-20 Aminothiazole derivatives

Publications (1)

Publication Number Publication Date
MX2010005824A true MX2010005824A (es) 2010-06-11

Family

ID=40430064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005824A MX2010005824A (es) 2007-11-30 2008-11-20 Derivados de aminotiazol.

Country Status (14)

Country Link
US (1) US7973051B2 (es)
EP (1) EP2227468A1 (es)
JP (1) JP2011504897A (es)
KR (1) KR20100080853A (es)
CN (1) CN101878211A (es)
AR (1) AR069435A1 (es)
AU (1) AU2008328955B2 (es)
BR (1) BRPI0820622A2 (es)
CA (1) CA2706574A1 (es)
IL (1) IL205751A0 (es)
MX (1) MX2010005824A (es)
PE (1) PE20091425A1 (es)
TW (1) TW200922563A (es)
WO (1) WO2009068467A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101990337B (zh) * 2009-08-03 2014-03-26 联咏科技股份有限公司 可动态维持定电流驱动的光源驱动装置及其相关方法
RU2557059C2 (ru) 2009-12-04 2015-07-20 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
EP3494119A4 (en) 2016-07-29 2020-03-25 Sunovion Pharmaceuticals Inc. CONNECTIONS AND COMPOSITIONS AND USES THEREOF
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
WO2020002090A1 (de) 2018-06-25 2020-01-02 Bayer Aktiengesellschaft Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3130849A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933355A (en) 1988-04-14 1990-06-12 Sankyo Company Limited Thiazole derivatives, their preparation and their use in the treatment of diabetes complications
TR199901816T2 (xx) * 1997-01-29 1999-11-22 Pfizer Inc S�lfonil �re t�revleri, bunlar�n interl�kin-1 aktivitesinin kontrol�nde kullan�mlar�.
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
JP2005510508A (ja) 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
BRPI0510095A (pt) * 2004-04-20 2007-10-16 Transtech Pharma Inc tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
CN101454301A (zh) * 2006-06-01 2009-06-10 霍夫曼-拉罗奇有限公司 噻唑衍生物

Also Published As

Publication number Publication date
AU2008328955B2 (en) 2012-12-13
PE20091425A1 (es) 2009-09-23
EP2227468A1 (en) 2010-09-15
AU2008328955A1 (en) 2009-06-04
CN101878211A (zh) 2010-11-03
US7973051B2 (en) 2011-07-05
WO2009068467A1 (en) 2009-06-04
BRPI0820622A2 (pt) 2015-06-16
JP2011504897A (ja) 2011-02-17
CA2706574A1 (en) 2009-06-04
AR069435A1 (es) 2010-01-20
TW200922563A (en) 2009-06-01
US20090143448A1 (en) 2009-06-04
IL205751A0 (en) 2010-11-30
KR20100080853A (ko) 2010-07-12

Similar Documents

Publication Publication Date Title
MX2010005824A (es) Derivados de aminotiazol.
MY138941A (en) Aryl-pyridine derivatives
TW200738241A (en) Pyridazine derivatives
TW200616976A (en) Pyrimidine derivatives
TW200740764A (en) Pyrazolone derivatives
TW200626558A (en) Indazolone derivatives
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
IN2012DN03337A (es)
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2010005714A (es) Compuestos de piridina.
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
IN2012DN01232A (es)
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2009010567A (es) Derivados de imidazolidinona.
MX2009003169A (es) Derivados de sulfonamida.
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2009013003A (es) Derivados de piperidina-amida.
MX2011011716A (es) Derivados de isoquinolina novedosos.
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
IN2012DN01234A (es)
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
WO2007145563A8 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor

Legal Events

Date Code Title Description
FG Grant or registration